Einschlußkörper in viruskrankenHesperis-Zellen

Zusammenfassung An einer Anzahl vonHesperis Candida undHesperis matronalis-Pflanzen zeigten sich im Botanischen Garten im Frühjahr 1959 Symptome einer Mosaikkrankheit. In den Trichomen der Blätter, in der Epidermis der Blattmittelrippe, in der Oberhaut des Stengels sowie in der Epidermis der Fruchtwand traten oft auffallend große protoplasmatische X-Körper auf. in denen sich Viruseiweißkristalle verschiedener Größe und Form bildeten.Herrn Professor Dr. Adolf Sperlich zum 80. Geburtstag.     

Developmental Changes in Glycolipid Synthesizing Enzymes in the Brain of a Myelin-Deficient Mutant Wistar Rat

Changes in the activities of UDP-galactose:ceramide galactosyltransferase (CGalT, EC 2.4.1.45), UDP-glucose:ceramide glucosyltransferase (CGlcT, EC 2.4.1.80) and 3'-phosphoadenosine-5'-phosphosulfate (PAPS): galactosylceramide 3'-sulfotransferase (EC 2.8.2.11) over the myelinating period between 12 and 25 days were studied in the brains of control and myelin-deficient rats. Although the activity of galactosyltransferase with ceramides containing hydroxy fatty acids quadrupled in normal male littermates between 14 and 20 days, hardly any increase was observed in the mutant and the activity was less than 10% of control above 20 days of age. With normal fatty acid containing ceramides as acceptors, the activity decreased from 83% of the control at 12 days to approximately 30% after 20 days. Sulfotransferase activity also did not show the normal increase during the 3rd week of life and declined from 60% to 22%. Glucosyltransferase and lysosomal hydrolases in brain and ceramide galactosyltransferase in sciatic nerves appeared to be normal. These results suggest close similarities to the jimpy mutant mouse in which myelin deficiency is also inherited as an x-linked recessive trait.     

The steady-state kinetic mechanism of ATP hydrolysis catalyzed by membrane-bound (Na+ + K+)-ATPase from ox brain IV. Rate constant determination

The expressions for the kinetic constants corresponding to the steady state model for hydrolysis of ATP catalyzed by (Na⁺ + K⁺)-ATPase proposed recently are analyzed with the object of determining the rate constants. The theoretical background for the necessary procedures is described. The results of this analysis are: (1) A small class (four) of rate constants are determined directly by the previously published values of the kinetic constants. (2) For a somewhat larger class of rate constants upper and lower bounds may be established. For several rate constants the upper and lower bounds differ by less than a factor 1.6 (for the ‘(Na⁺ + K⁺)-enzyme’, i.e. the enzyme activity with K⁺ and millimolar substrate concentration) and 1.2 (for the ‘Na⁺-enzyme’, i.e. the activity at micromolar substrate concentrations). (3) Experiments on inhibition by K⁺ of the Na⁺-enzyme at various Mg²⁺ concentrations are reported and analyzed. With the additional assumption that the rate constants governing the addition to ATP of Mg²⁺ is independent of whether or not ATP is bound to an enzyme molecule, a set of consistent values for all the 23 rate constants in the mechanism may be obtained. (4) The values of some rate constants lend further support to the contention discussed in a previous paper that the enzyme hydrolyzes ATP along two kinetically distinct pathways, depending on the presence of K⁺ and on the concentration of substrate, without the necessity of having more than one active substrate site per enzyme unit at any time. (5) The results show that while the two enzyme forms, the ‘Na⁺-enzyme’ E₁ and the “K⁺-enzyme” E₂K, add substrate with (second order) rate constants of the same order of magnitude (differing only by a factor of four in favor of the former), the rate constants for the reverse processes differ by a factor of 100, being largest for the K⁺-enzyme. This is the main reason for the large difference in the Michaelis constants for the two forms reported previously. (6) Compatibility of the model with the well-known rapid dephosphorylation of the phosphorylated enzyme in the presence of K⁺ requires the presence, at non-zero steady state concentration, of an enzyme-potassium-phosphate intermediate, which is acid labile and is therefore not detected as a phosphorylated enzyme using conventional methods.     

[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts

Introduction

APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.

Methods

In vivo uptake of [18F]FLT and [18F]FDG in human ovary cancer xenografts in mice (A2780) was studied at various time points after APO866 treatment. Baseline [18F]FLT or [18F]FDG scans were made before treatment and repeated after 24 hours, 48 hours and 7 days. Tumor volume was followed with computed tomography (CT). Tracer uptake was quantified using small animal PET/CT. One hour after iv injection of tracer, static PET scans were performed. Imaging results were compared with Ki67 immunohistochemistry.

Results

Tumors treated with APO866 had volumes that were 114% (24 h), 128% (48 h) and 130% (Day 7) relative to baseline volumes at Day 0. In the control group tumor volumes were 118% (24 h), 145% (48 h) and 339% (Day 7) relative to baseline volumes Day 0. Tumor volume between the treatment and control group was significantly different at Day 7 (P = 0.001). Compared to baseline, [18F]FLT SUVmax was significantly different at 24 h (P<0.001), 48 h (P<0.001) and Day 7 (P<0.001) in the APO866 group. Compared to baseline, [18F]FDG SUVmax was significantly different at Day 7 (P = 0.005) in the APO866 group.

Conclusions

APO866 treatment caused a significant decrease in [18F]FLT uptake 24 and 48 hours after treatment initiation. The early reductions in tumor cell proliferation preceded decrease in tumor volume. The results show the possibility to use [18F]FLT and [18F]FDG to image treatment effect early following treatment with APO866 in future clinical studies.     

Subclinical Thyroid Dysfunction and Cognitive Decline in Old Age

Background

Subclinical thyroid dysfunction has been implicated as a risk factor for cognitive decline in old age, but results are inconsistent. We investigated the association between subclinical thyroid dysfunction and cognitive decline in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).

Methods

Prospective longitudinal study of men and women aged 70–82 years with pre-existing vascular disease or more than one risk factor to develop this condition (N = 5,154). Participants taking antithyroid medications, thyroid hormone supplementation and/or amiodarone were excluded. Thyroid function was measured at baseline: subclinical hyper- and hypothyroidism were defined as thyroid stimulating hormones (TSH) <0.45 mU/L or >4.50 mU/L respectively, with normal levels of free thyroxine (FT4). Cognitive performance was tested at baseline and at four subsequent time points during a mean follow-up of 3 years, using five neuropsychological performance tests.

Results

Subclinical hyperthyroidism and hypothyroidism were found in 65 and 161 participants, respectively. We found no consistent association of subclinical hyper- or hypothyroidism with altered cognitive performance compared to euthyroid participants on the individual cognitive tests. Similarly, there was no association with rate of cognitive decline during follow-up.

Conclusion

We found no consistent evidence that subclinical hyper- or hypothyroidism contribute to cognitive impairment or decline in old age. Although our data are not in support of treatment of subclinical thyroid dysfunction to prevent cognitive dysfunction in later life, only large randomized controlled trials can provide definitive evidence.     

German network on life cycle inventory data

Reliability of Life Cycle Assessment (LCA) results depends on the availability and quality of Life Cycle Inventory (LCI) data. In order to provide high-quality LCI data for background systems in LCA and to make it applicable to a wider range of fields, harmonization strategies for already existing datasets and databases are required. In view of the high significance of LCI data as a basis of major fields of action within a sustainability strategy, the German Helmholtz Association (HGF), under the leadership of the Forschungszentrum Karlsruhe (FZK) has taken up this issue in its research programme. In 2002, the FZK conducted a preliminary study on ‘Quality Assurance and User-oriented Supply of a Life Cycle Inventory Data’ funded by the Federal Ministry of Education and Research (BMBF). Within the framework of this study, a long-term concept for improving the scientific fundamentals and practical use of LCI data was developed in association with external experts. The focus is on establishing a permanent German ‘Network on Life Cycle Inventory Data’ which will serve as the German information and cooperation platform for all scientific and non-scientific actors in the field of life cycle analysis. This network will integrate expertise on LCA in Germany, harmonise methodology and data, and use the comprehensive expert panel as an efficient basis for further scientific development and practical use of LCA. At the same time, this network will serve as a platform for cooperation on an international level. Current developments address methodological definitions for the initial information infrastructure. As a novel element, user needs are differentiated in parallel according to the broad application fields of LCI-data from product declaration to process design. Case studies will be used to define tailored interfaces for the database, since different data quality levels will be encountered.